Chinese Journal of Tissue Engineering Research ›› 2011, Vol. 15 ›› Issue (2): 368-372.doi: 10.3969/j.issn.1673-8225.2011.02.044

Previous Articles     Next Articles

Meta analysis of trimetazidine in the treatment of dilated cardiomyopathy 

Gong Ren, Huang Xiao, Wu Yan-qing   

  1. Provincial Key Laboratory of Molecular Medicine, Department of Cardiology, Second Hospital, Nanchang University, Nanchang  330006, Jiangxi Province, China
  • Received:2010-07-20 Revised:2010-09-05 Online:2011-01-08 Published:2011-01-08
  • Contact: Wu Yan-qing, Doctor, Professor, Master’s supervisor, Provincial Key Laboratory of Molecular Medicine, Department of Cardiology, Second Hospital, Nanchang University, Nanchang 330006, Jiangxi Province, China wuyanqing01@sina.com
  • About author:Gong Ren★, Studying for master’s degree, Provincial Key Laboratory of Molecular Medicine, Department of Cardiology, Second Hospital, Nanchang University, Nanchang 330006, Jiangxi Province, China gongren.student@sina.com
  • Supported by:

    the Youth Foundation, the National Natural Science Foundation of China, No. 08300846

PDF

401

Abstract:

BACKGROUND: Trimetazidine has shown safety and efficacy in the treatment of ischemic heart disease, whether it has similar effect on treating dilated cardiomyopathy remains unclear. 
OBJECTIVE: To evaluate the efficacy and safety of Trimetazidine in the treatment of dilated cardiomyopathy.
METHODS: Cochrane, PubMed, Medline and China National Knowledge Infrastructure (CNKI) databases were searched for the literatures on the clinical trials of Trimetazidine in the treatment of dilated cardiomyopathy using key words of “Trimetazidine, dilated cardiomyopathy”. A manual search of those trials was simultaneously performed. A meta-analysis was conducted on the outcomes of the included trials with the assistance of RevMan 4.2.2 software.
RESULTS AND CONCLUSION: Totally 6 of the randomized controlled trials including 339 patients were analyzed, and 1 study was of high methodological quality. Meta-analysis indicated that, compared with control group, the rehospitalization rate of the Trimetazidine group was decreased, OR=0.21(95% CI, 0.07-0.59)> 0, Z value was 2.98 (P=0.003), mortality declined OR=0.14(95% CI, 0.03-0.69)> 0, Z value was 2.43 (P=0.01), and the walking distance increased, OR=57.27(95% CI, 46.17-72.38)> 0, Z value was 8.86 (P < 0.000 01). The left ventricular ejection fraction of the Trimetazidine group was greater the control group (conventional therapy group) at the end of follow-up, OR=2.44(95% CI, 0.89-3.99)> 0, Z value was 3.08 (P < 0.002), and the left ventricular end diastolic diameter was obviously minificated, OR=-1.42 (95% CI, -5.06 to -3.18)< 0, Z value was 8.57 (P < 0.000 01). These findings demonstrated that, it is safe and effective to treat dilated cardiomyopathy using Trimetazidine.

CLC Number: